Pappas Capital LLC
01/27/2015 | Press release | Archived content
Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515...
News | 01. 27. 2015
Envisia Therapeutics
RESEARCH TRIANGLE PARK, NC - JANUARY 27, 2015 - Envisia Therapeutics today announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. ENV515is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particleformulation of a prostaglandin analog, travoprost, with the potential forsustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offersthe potential to significantly address the poor compliance that exists among glaucoma patients today to limit disease progression and vision loss.
Pappas Capital LLC published this content on January 27, 2015, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]